Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?
作者信息
Lawson D H, Henry D A
出版信息
Br Med J. 1977 Mar 12;1(6062):691-2. doi: 10.1136/bmj.1.6062.691.
Abstract
摘要
相似文献
1
Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?监测新药的不良反应：“限制发布”还是“监测发布”？
Br Med J. 1977 Mar 12;1(6062):691-2. doi: 10.1136/bmj.1.6062.691.
2
Monitoring adverse reactions to drugs.监测药物不良反应。
Br Med J. 1977 Jan 8;1(6053):96-7. doi: 10.1136/bmj.1.6053.96.
3
Monitoring of drugs after marketing.药品上市后监测
J R Coll Gen Pract. 1983 Jul;33(252):438-41.
4
New strategies for drug monitoring.药物监测的新策略。
Br Med J. 1977 Apr 2;1(6065):861-2.
5
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
6
Systems for evaluation of new drugs in the United Kingdom.英国新药评估体系
Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):439-43. doi: 10.1002/pds.596.
7
Reorganization of the National Health Service: background and issues in England's quest for a comprehensive-integrated planning and delivery system.
Milbank Mem Fund Q Health Soc. 1973 Fall;51(4):489-530.
8
A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.关于英国人体潜在新药研究指南的思考。
Methods Find Exp Clin Pharmacol. 1979 Apr;1(1):45-50.
9
Performance monitoring. New look at examining output.
Health Serv J. 1986 Sep 18;96(5017):1231.
10
Evaluating drugs: a new approach.
Br Med J. 1977 Nov 19;2(6098):1302.
引用本文的文献
1
European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.
Eur J Clin Pharmacol. 1995;49(1-2):73-9. doi: 10.1007/BF00192362.
2
Postmarketing surveillance: practical experience with ketotifen.上市后监测：酮替芬的实际应用经验
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):911-4. doi: 10.1136/bmj.288.6421.911.
3
Postmarketing surveillance of adverse reactions to drugs.药品不良反应的上市后监测。
Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):879-80. doi: 10.1136/bmj.288.6421.879.
4
Postmarketing surveillance of the safety of cimetidine: 12 month mortality report.西咪替丁安全性的上市后监测：12个月死亡率报告。
Br Med J (Clin Res Ed). 1983 May 28;286(6379):1713-6. doi: 10.1136/bmj.286.6379.1713.
5
Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?新药不良反应的识别。I：自沙利度胺事件以来有哪些重要的不良反应？
Br Med J (Clin Res Ed). 1983 Jan 15;286(6360):199-202. doi: 10.1136/bmj.286.6360.199.
6
Post-marketing surveillance in the UK (1984).英国的上市后监测（1984年）。
Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x.
7
Post marketing surveillance of captopril (for hypertension): a preliminary report.卡托普利（用于治疗高血压）的上市后监测：初步报告。
Br J Clin Pharmacol. 1987 Sep;24(3):343-9. doi: 10.1111/j.1365-2125.1987.tb03179.x.
8
Post-marketing surveillance of adverse reactions to new medicines.新药不良反应的上市后监测
Br Med J. 1977 Oct 15;2(6093):1001-3. doi: 10.1136/bmj.2.6093.1001.
9
Once is not enough.
Eur J Clin Pharmacol. 1977;11(5):323-4. doi: 10.1007/BF00566527.
10
Monitoring adverse reactions to drugs.监测药物不良反应。
Br Med J. 1977 Apr 30;1(6069):1159. doi: 10.1136/bmj.1.6069.1159-c.
Zotero 插件